Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,441 to 2,460 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| M-M-R II ® vs Placebo: Severity of COVID-19 Measured at 60 Days After Intervention | 3 of 1,607 1 of 1,544 | 0.1 points -0.2 to 0.5 | 3,151 | NCT04333732 CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION |
| Rotarix Group vs Placebo Group: Number of Subjects With Any Episode(s) of Rotavirus Gastroenteritis (RVGE) Caused by the Circulating Wild-type Strains | 70 of 1,575 167 of 1,573 | -6.2 points -8.0 to -4.3 | 3,148 | NCT01171963 Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants |
| Rotarix Group vs Placebo Group: Number of Subjects With Episodes of Rotavirus Gastroenteritis (RVGE) Caused by the Circulating Wild Type (WT) Strains Requiring Hospitalization | 4 of 1,575 21 of 1,573 | -1.1 points -1.8 to -0.5 | 3,148 | NCT01171963 Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants |
| Rotarix Group vs Placebo Group: Number of Subjects With Severe Episode(s) of Rotavirus Gastroenteritis (RVGE) Caused by the Circulating Wild Type (WT) Strains | 21 of 1,575 75 of 1,573 | -3.4 points -4.7 to -2.3 | 3,148 | NCT01171963 Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants |
| Lapatinib 1500 mg vs Placebo: Number of Participants With CNS Recurrence | 15 of 1,571 21 of 1,576 | -0.4 points -1.2 to 0.4 | 3,147 | NCT00374322 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer |
| Lapatinib 1500 mg vs Placebo: Number of Participants With Any Recurrence of the Initial Disease, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS]) | 184 of 1,571 231 of 1,576 | -2.9 points -5.3 to -0.6 | 3,147 | NCT00374322 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer |
| Lapatinib 1500 mg vs Placebo: serious adverse events | 99 of 1,573 78 of 1,574 | 1.3 points -0.3 to 3.0 | 3,147 | NCT00374322 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Any Repeat Revascularization | 202 of 2,372 76 of 769 | -1.4 points -3.9 to 0.9 | 3,141 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Rate of Stent Thrombosis | 27 of 2,364 16 of 771 | -0.9 points -2.3 to 0.0 | 3,135 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Ischemia-driven Target Vessel Revascularization | 133 of 2,366 41 of 766 | 0.3 points -1.8 to 2.0 | 3,132 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Ischemia-driven Target Lesion Revascularization | 117 of 2,364 38 of 766 | -0.0 points -2.0 to 1.6 | 3,130 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| M-M-R II ® vs Placebo: Number of Participants With Symptomatic COVID-19 at 150 Days | 65 of 1,585 64 of 1,544 | -0.0 points -1.5 to 1.4 | 3,129 | NCT04333732 CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION |
| M-M-R II ® vs Placebo: Severity of COVID-19 at 150 Days After Intervention | 3 of 1,585 1 of 1,544 | 0.1 points -0.2 to 0.5 | 3,129 | NCT04333732 CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION |
| Enhanced Treatment vs Current Practice: serious adverse events | 6 of 1,017 15 of 2,108 | -0.1 points -0.7 to 0.6 | 3,125 | NCT00513500 Zambia Integrated Management of Malaria and Pneumonia Study |
| Bone Health Service Arm vs Usual Care (Control) Arm: Proportion With Fractures | 31 of 1,688 29 of 1,424 | -0.2 points -1.2 to 0.8 | 3,112 | NCT04079868 Models of Primary Osteoporosis Screening in Male Veterans |
| Bone Health Service Arm vs Usual Care (Control) Arm: Proportion of Participants Screened for Osteoporosis | 830 of 1,688 33 of 1,424 | 46.9 points 44.3 to 49.3 | 3,112 | NCT04079868 Models of Primary Osteoporosis Screening in Male Veterans |
| Bone Health Service Arm vs Usual Care (Control) Arm: Gastrointestinal Medication Prescriptions | 562 of 1,688 473 of 1,424 | 0.1 points -3.2 to 3.4 | 3,112 | NCT04079868 Models of Primary Osteoporosis Screening in Male Veterans |
| Bone Health Service Arm vs Usual Care (Control) Arm: deaths from any cause | 135 of 1,688 89 of 1,424 | 1.7 points -0.1 to 3.5 | 3,112 | NCT04079868 Models of Primary Osteoporosis Screening in Male Veterans |
| Pre-intervention vs Post-intervention: serious adverse events | 165 of 1,574 95 of 1,532 | 4.3 points 2.3 to 6.2 | 3,106 | NCT02320175 Bringing I-PASS to the Bedside: A Communication Bundle to Improve Patient Safety and Experience |
| FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI vs Non-Ellipta MITT: deaths from any cause | 8 of 1,545 8 of 1,547 | 0.0 points -0.6 to 0.6 | 3,092 | NCT03467425 INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design |
Code
curl "https://conductscience.org/api/comparisons/v1?page=123"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=123
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04333732-7d39caf8",
"title": "M-M-R II ® vs Placebo: Severity of COVID-19 Measured at 60 Days After Intervention",
"summary": "3 of 1607 against 1 of 1544; risk difference 0.1 points, 95% interval -0.2 to 0.5; NCT04333732, CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION",
"record": "/library/comparisons/NCT04333732-7d39caf8",
"nct_id": "NCT04333732",
"kind": "outcome",
"participants": 3151,
"risk_difference": {
"value": 0.0012191642135604914,
"lower": -0.0020348982631645607,
"upper": 0.004865965109806117
},
"group_1": "3 of 1,607",
"group_2": "1 of 1,544",
"difference": "0.1 points",
"interval": "-0.2 to 0.5",
"trial_title": "CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION"
},
{
"id": "NCT01171963-36865e1e",
"title": "Rotarix Group vs Placebo Group: Number of Subjects With Any Episode(s) of Rotavirus Gastroenteritis (RVGE) Caused by the Circulating Wild-type Strains",
"summary": "70 of 1575 against 167 of 1573; risk difference -6.2 points, 95% interval -8.0 to -4.3; NCT01171963, Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants",
"record": "/library/comparisons/NCT01171963-36865e1e",
"nct_id": "NCT01171963",
"kind": "outcome",
"participants": 3148,
"risk_difference": {
"value": -0.06172211626757081,
"lower": -0.08030643024848949,
"upper": -0.04349454700825449
},
"group_1": "70 of 1,575",
"group_2": "167 of 1,573",
"difference": "-6.2 points",
"interval": "-8.0 to -4.3",
"trial_title": "Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=124",
"request_id": "pSwDq8wc103iLi2P"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant